Cell Bio Human Tech Past Earnings Performance
Past criteria checks 0/6
Cell Bio Human Tech's earnings have been declining at an average annual rate of -166.6%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 1% per year.
Key information
-166.6%
Earnings growth rate
-155.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -1.0% |
| Return on equity | -4.2% |
| Net Margin | -6.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Cell Bio Human Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27,324 | -1,857 | 3,594 | 657 |
| 30 Sep 23 | 26,254 | -902 | 3,466 | 472 |
| 30 Jun 23 | 27,332 | 994 | 3,212 | 619 |
| 31 Mar 23 | 27,092 | 3,010 | 3,106 | 690 |
| 30 Sep 22 | 28,112 | 2,564 | 3,051 | 990 |
| 31 Mar 22 | 30,492 | 1,565 | 3,514 | 801 |
Quality Earnings: A318160 is currently unprofitable.
Growing Profit Margin: A318160 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A318160's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A318160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A318160 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A318160 has a negative Return on Equity (-4.17%), as it is currently unprofitable.